Contribution of macrophage polarization to metabolic diseases

Journal of Atherosclerosis and Thrombosis

Volumn 23, Issue 1, 2016, Pages 10-17

  Komohara, Yoshihiro ^a   Fujiwara, Yukio ^a   Ohnishi, Koji ^a   Shiraishi, Daisuke ^a   Takeya, Motohiro ^a  

^a KUMAMOTO UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Heterogeneity; Macrophage; Non alcoholic fatty liver disease; Obesity

Indexed keywords

CD163 ANTIGEN; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLYCOPROTEIN P 15095; HERMES ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; ONCOSTATIN M; PENTRAXIN 3; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; GLUCAGON LIKE PEPTIDE 1;

ATHEROSCLEROSIS; HUMAN; IMMUNE RESPONSE; MACROPHAGE ACTIVATION; MACROPHAGE POLARIZATION; METABOLIC DISORDER; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; PATHOGENESIS; PHENOTYPE; POLARIZATION; PROTEIN EXPRESSION; REVIEW; TH1 CELL; TH2 CELL; AGONISTS; ANIMAL; CYTOLOGY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; IMMUNOLOGY; LIVER DISEASE; MACROPHAGE; METABOLISM; MOUSE;

ANIMALS; ATHEROSCLEROSIS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GLUCAGON-LIKE PEPTIDE 1; HUMANS; LIVER DISEASES; MACROPHAGE ACTIVATION; MACROPHAGES; METABOLIC DISEASES; MICE; OBESITY; ONCOSTATIN M; PHENOTYPE; TH1 CELLS; TH2 CELLS;

EID: 84953388280     PISSN: 13403478     EISSN: 18803873     Source Type: Journal    
DOI: 10.5551/jat.32359     Document Type: Review

References (58)

1. Burke B, Lewis CE: The Macrophage, Oxford University Press, Oxford, UK, 2002
2. Varin A, Gordon S: Alternative activation of macrophages: immune function and cellular biology. Immunobiology, 2009; 214: 630-641
3. Sica A, Mantovani A: Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012; 122: 787-795
4. Takahashi K, Naito M, Takeya M: Development and heterogeneity of macrophages and their related cells through their differentiation pathways. Pathol Int, 1996; 46: 473-485
5. Schulz C, Gomez Perdiguero E, Chorro L, Szabo-Rogers H, Cagnard N, Kierdorf K, Prinz M, Wu B, Jacobsen SE, Pollard JW, Frampton J, Liu KJ, Geissmann F: A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science, 2012; 336: 86-90
6. Gordon S: Alternative activation of macrophages. Nat Rev Immunol, 2003; 3: 23-35
7. Mills CD: M1 and M2 Macrophages: Oracles of Health and Disease. Crit Rev Immunol, 2012; 32: 463-488
8. Martinez FO, Gordon S, Locati M, Mantovani A: Transcriptional profiling of the human monocyte-to-macrophage differentiation and polarization: new molecules and patterns of gene expression. J Immunol, 2006; 177: 7303-7311
9. Komohara Y, Niino D, Ohnishi K, Ohshima K, Takeya M: Role of tumor-associated macrophages in hematological malignancies. Pathol Int, 2015; 65: 170-176
10. Komohara Y, Jinushi M, Takeya M: Clinical significance of macrophage heterogeneity in human malignant tumors. Cancer Sci, 2014; 105: 1-8
11. Farrell GC, van Rooyen D, Gan L, Chitturi S: NASH is an Inflammatory Disorder: Pathogenic, Prognostic and Therapeutic Implications. Gut Liver, 2012; 6: 149-171
12. Furusho H, Miyauchi M, Hyogo H, Inubushi T, Ao M, Ouhara K, Hisatune J, Kurihara H, Sugai M, Hayes CN, Nakahara T, Aikata H, Takahashi S, Chayama K, Takata T: Dental infection of Porphyromonas gingivalis exacerbates high fat diet-induced steatohepatitis in mice. J Gastroenterol, 2013; 48: 1259-1270
13. Ramadori G, Armbrust T: Cytokines in the liver. Eur J Gastroenterol Hepatol, 2001; 13: 777-784
14. Miura K, Kodama Y, Inokuchi S, Schnabl B, Aoyama T, Ohnishi H, Olefsky JM, Brenner DA, Seki E: Toll-like receptor 9 promotes steatohepatitis by induction of interleukin- 1beta in mice. Gastroenterology, 2010; 139: 323-334
15. Tosello-Trampont AC, Landes SG, Nguyen V, Novo brantseva TI, Hahn YS: Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem, 2012; 287: 40161-40172
16. Itoh M, Kato H, Suganami T, Konuma K, Marumoto Y, Terai S, Sakugawa H, Kanai S, Hamaguchi M, Fukaishi T, Aoe S, Akiyoshi K, Komohara Y, Takeya M, Sakaida I, Ogawa Y: Hepatic crown-like structure: a unique histological feature in non-alcoholic steatohepatitis in mice and humans. PLoS One, 2013; 8: e82163
17. Kazankov K, Tordjman J, Møller HJ, Vilstrup H, Poitou C, Bedossa P, Bouillot JL, Clement K, Grønbaek H: The macrophage activation marker sCD163 is independently associated with NAFLD severity in morbid obesity and reduced by bariatric surgery. J Gastroenterol Hepatol. 2015 (in press).
18. Wan J, Benkdane M, Alons E, Lotersztajn S, Pavoine C: M2 kupffer cells promote hepatocyte senescence: an IL-6- dependent protective mechanism against alcoholic liver disease. Am J Pathol, 2014; 184: 1763-1772
19. Maina V, Sutti S, Locatelli I, Vidali M, Mombello C, Bozzola C, Albano E: Bias in macrophage activation pattern influences non-alcoholic steatohepatitis (NASH) in mice. Clin Sci (Lond), 2012; 122: 545-553
20. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW: Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest, 2003; 112: 1796-1808
21. Jenkins SJ, Ruckerl D, Cook PC, Jones LH, Finkelman FD, van Rooijen N, MacDonald AS, Allen JE: Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science, 2011; 332: 1284-1288
22. Nomiyama T, Perez-Tilve D, Ogawa D, Gizard F, Zhao Y, Heywood EB, Jones KL, Kawamori R, Cassis LA, Tschöp MH, Bruemmer D: Osteopontin mediates obesityinduced adipose tissue macrophage infiltration and insulin resistance in mice. J Clin Invest, 2007; 117: 2877-2888
23. Amano SU, Cohen JL, Vangala P, Tencerova M, Nicoloro SM, Yawe JC, Shen Y, Czech MP, Aouadi M: Local proliferation of macrophages contributes to obesity-associated adipose tissue inflammation. Cell Metab, 2014; 19: 162-171
24. Eguchi K, Manabe I: Toll-like receptor, lipotoxicity and chronic inflammation: the pathological link between obesity and cardiometabolic disease. J Atheroscler Thromb, 2014; 21: 629-639
25. Hill AA, Reid Bolus W, Hasty AH: A decade of progress in adipose tissue macrophage biology. Immunol Rev, 2014; 262: 134-152
26. Suganami T, Nishida J, Ogawa Y: A paracrine loop between adipocytes and macrophages aggravates inflammatory changes: role of free fatty acids and tumor necrosis factor alpha. Arterioscler Thromb Vasc Biol, 2005; 25: 2062-2068
27. Stienstra R, Joosten LA, Koenen T, van Tits B, van Diepen JA, van den Berg SA, Rensen PC, Voshol PJ, Fantuzzi G, Hijmans A, Kersten S, Müller M, van den Berg WB, van Rooijen N, Wabitsch M, Kullberg BJ, van der Meer JW, Kanneganti T, Tack CJ, Netea MG: The inflamma some-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab, 2010; 12: 593-605
28. Cancello R, Henegar C, Viguerie N, Taleb S, Poitou C, Rouault C, Coupaye M, Pelloux V, Hugol D, Bouillot JL, Bouloumié A, Barbatelli G, Cinti S, Svensson PA, Barsh GS, Zucker JD, Basdevant A, Langin D, Clément K: Reduction of macrophage infiltration and chemoattractant gene expression changes in white adipose tissue of morbidly obese subjects after surgery-induced weight loss. Diabetes, 2005; 54: 2277-2286
29. Huang ZH, Manickam B, Ryvkin V, Zhou XJ, Fantuzzi G, Mazzone T, Sam S: PCOS is associated with increased CD11c expression and crown-like structures in adipose tissue and increased central abdominal fat depots independent of obesity. J Clin Endocrinol Metab, 2013; 98: E17-E24
30. Kodama K, Horikoshi M, Toda K, Yamada S, Hara K, Irie J, Sirota M, Morgan AA, Chen R, Ohtsu H, Maeda S, Kadowaki T, Butte AJ: Expression-based genome-wide association study links the receptor CD44 in adipose tissue with type 2 diabetes. Proc Natl Acad Sci U S A, 2012; 109: 7049-7054
31. Liu LF, Kodama K, Wei K, Tolentino LL, Choi O, Engleman EG, Butte AJ, McLaughlin T: The receptor CD44 is associated with systemic insulin resistance and proinflammatory macrophages in human adipose tissue. Diabetologia, 2015; 58: 1579-1586
32. Stienstra R, Duval C, Keshtkar S, van der Laak J, Kersten S, Müller M: Peroxisome proliferator-activated receptor gamma activation promotes infiltration of alternatively activated macrophages into adipose tissue. J Biol Chem, 2008; 283: 22620-22627
33. Tipping PG Hancock WW: Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques. Am J Pathol, 1993; 142: 1721-1728
34. Rosklint T, Ohlsson BG, Wiklund O, Norén K, Hultén LM: Oxysterols induce interleukin-1beta production in human macrophages. Eur J Clin Invest, 2002; 32: 35-42
35. Chinetti-Gbaguidi G, Baron M, Bouhlel MA, Vanhoutte J, Copin C, Sebti Y, Derudas B, Mayi T, Bories G, Tailleux A, Haulon S, Zawadzki C, Jude B, Staels B: Human atherosclerotic plaque alternative macrophages display low cholesterol handling but high phagocytosis because of distinct activities of the PPARγ and LXRα pathways. Circ Res, 2011; 108: 985-995
36. Komohara Y, Hirahara J, Horikawa T, Kawamura K, Kiyota E, Sakashita N, Araki N, Takeya M: AM-3K, an anti-macrophage antibody, recognizes CD163, a molecule associated with an anti-inflammatory macrophage phenotype. J Histochem Cytochem, 2006; 54: 763-771
37. Khallou-Laschet J, Varthaman A, Fornasa G, Compain C, Gaston AT, Clement M, Dussiot M, Levillain O, Graff- Dubois S, Nicoletti A, Caligiuri G: Macrophage plasticity in experimental atherosclerosis. PLoS One, 2010; 5: e8852
38. Tousoulis D, Antoniades C, Koumallos N, Stefanadis C: Pro-inflammatory cytokines in acute coronary syndromes: from bench to bedside. Cytokine Growth Factor Rev, 2006; 17: 225-233
39. Usman A, Ribatti D, Sadat U, Gillard JH: From Lipid Retention to Immune-Mediate Inflammation and Associated Angiogenesis in the Pathogenesis of Atherosclerosis. J Atheroscler Thromb, 2015; 22: 739-749
40. Inoue K, Kodama T, Daida H: Pentraxin 3: a novel biomarker for inflammatory cardiovascular disease. Int J Vasc Med, 2012; 2012: 657025
41. Savchenko A, Imamura M, Ohashi R, Jiang S, Kawasaki T, Hasegawa G, Emura I, Iwanari H, Sagara M, Tanaka T, Hamakubo T, Kodama T, Naito M: Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol, 2008; 215: 48-55
42. Imamura M, Kawasaki T, Savchenko AS, Ohashi R, Jiang S, Miyamoto K, Ito Y, Iwanari H, Sagara M, Tanaka T, Hamakubo T, Kodama T, Uchiyama M, Naito M. Lipopolysaccharide induced expression of pentraxin 3 in human neutrophils and monocyte-derived macrophages. Cell Immunol, 2007; 248: 86-94
43. Bonavita E, Gentile S, Rubino M, Maina V, Papait R, Kunderfranco P, Greco C, Feruglio F, Molgora M, Laface I, Tartari S, Doni A, Pasqualini F, Barbati E, Basso G, Galdiero MR, Nebuloni M, Roncalli M, Colombo P, Laghi L, Lambris JD, Jaillon S, Garlanda C, Mantovani A: PTX3 is an extrinsic oncosuppressor regulating complement- dependent inflammation in cancer. Cell, 2015; 160: 700-714
44. Matsuura Y, Hatakeyama K, Imamura T, Tsuruda T, Shibata Y, Kodama T, Kitamura K, Asada Y: Different distribution of pentraxin 3 and C-reactive protein in coronary atherosclerotic plaques. J Atheroscler Thromb, 2012; 19: 837-845
45. Elton TS, Selemon H, Elton SM, Parinandi NL: Regulation of the MIR155 host gene in physiological and pathological processes. Gene, 2013; 532: 1-12
46. Nazari-Jahantigh M, Wei Y, Noels H, Akhtar S, Zhou Z, Koenen RR, Heyll K, Gremse F, Kiessling F, Grommes J, Weber C, Schober A: MicroRNA-155 promotes atherosclerosis by repressing Bcl6 in macrophages. J Clin Invest, 2012; 122: 4190-4202
47. Kielgast U, Holst JJ, Madsbad S: Treatment of type 1 diabetic patients with glucagon-like peptide-1 (GLP-1) and GLP-1R agonists. Curr Diabetes Rev, 2009; 5: 266-275
48. Shiraishi D, Fujiwara Y, Komohara Y, Mizuta H, Takeya M: Glucagon-like peptide-1 (GLP-1) induces M2 polarization of human macrophages via STAT3 activation. Biochem Biophys Res Commun, 2012; 425: 304-308
49. Kawaguchi T, Itou M, Taniguchi E, Sata M: Exendin-4, a glucagon-like peptide-1 receptor agonist, modulates hepatic fatty acid composition and ∆-5-desaturase index in a murine model of non-alcoholic steatohepatitis. Int J Mol Med, 2014; 34: 782-787
50. Tomas E, Stanojevic V, McManus K, Khatri A, Everill P, Bachovchin WW, Habener JF: GLP-1(32-36)amide Pentapeptide Increases Basal Energy Expenditure and Inhibits Weight Gain in Obese Mice. Diabetes, 2015; 64: 2409-2419
51. Jensterle M, Kravos NA, Pfeifer M, Kocjan T, Janez A: A 12-week treatment with the long-acting glucagon-like peptide 1 receptor agonist liraglutide leads to significant weight loss in a subset of obese women with newly diagnosed polycystic ovary syndrome. Hormones (Athens), 2015; 14: 81-90
52. Hogan AE, Gaoatswe G, Lynch L, Corrigan MA, Woods C, O’Connell J, O’Shea D: Glucagon-like peptide 1 analogue therapy directly modulates innate immune-mediated inflammation in individuals with type 2 diabetes mellitus. Diabetologia, 2014; 57: 781-784
53. Katakami N, Mita T, Yoshii H, Onuma T, Kaneto H, Osonoi T, Shiraiwa T, Kosugi K, Umayahara Y, Yamamoto T, Yokoyama H, Kuribayashi N, Jinnouchi H, Gosho M, Watada H, Shimomura I; Collaborators on the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis Trial: Rationale, design, and baseline characteristics of a trial for the prevention of diabetic atherosclerosis using a DPP-4 inhibitor: the Study of Preventive Effects of Alogliptin on Diabetic Atherosclerosis (SPEADA). J Atheroscler Thromb, 2013; 20: 893-902
54. Guihard P, Danger Y, Brounais B, David E, Brion R, Delecrin J, Richards CD, Chevalier S, Rédini F, Heymann D, Gascan H, Blanchard F: Induction of osteogenesis in mesenchymal stem cells by activated monocytes/ macrophages depends on oncostatin M signaling. Stem Cells, 2012; 30: 762-772
55. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y: Lack of oncostatin M receptor β leads to adipose tissue inflammation and insulin resistance by switching macrophage phenotype. J Biol Chem, 2013; 288: 21861-21875
56. Komori T, Tanaka M, Senba E, Miyajima A, Morikawa Y: Deficiency of oncostatin M receptor β (OSMR β) exacerbates high-fat diet-induced obesity and related metabolic disorders in mice. J Biol Chem, 2014; 289: 13821-13837
57. Komori T, Tanaka M, Furuta H, Akamizu T, Miyajima A, Morikawa Y: Oncostatin M is a potential agent for the treatment of obesity and related metabolic disorders: a study in mice. Diabetologia. 2015 (in press).
58. Sanchez-Infantes D, White UA, Elks CM, Morrison RF, Gimble JM, Considine RV, Ferrante AW, Ravussin E, Stephens JM: Oncostatin m is produced in adipose tissue and is regulated in conditions of obesity and type 2 diabetes. J Clin Endocrinol Metab, 2014; 99: E217-E225